Foghorn Therapeutics Inc.
FHTX
$4.57
-$0.015-0.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.60M | 25.52M | 35.19M | 33.90M | 34.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.60M | 25.52M | 35.19M | 33.90M | 34.16M |
| Cost of Revenue | 117.40M | 130.68M | 131.20M | 131.20M | 135.65M |
| Gross Profit | -94.79M | -105.16M | -96.01M | -97.30M | -101.50M |
| SG&A Expenses | 28.36M | 29.03M | 30.37M | 31.44M | 32.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.89M | 127.25M | 130.15M | 136.68M | 142.06M |
| Operating Income | -100.29M | -101.74M | -94.97M | -102.78M | -107.91M |
| Income Before Tax | -86.62M | -89.24M | -83.72M | -89.29M | -94.20M |
| Income Tax Expenses | -- | 1.99M | 2.72M | 3.67M | 4.23M |
| Earnings from Continuing Operations | -86.62 | -91.22 | -86.45 | -92.95 | -98.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.62M | -91.22M | -86.45M | -92.95M | -98.43M |
| EBIT | -100.29M | -101.74M | -94.97M | -102.78M | -107.91M |
| EBITDA | -97.17M | -98.53M | -91.63M | -99.36M | -104.46M |
| EPS Basic | -1.65 | -1.91 | -1.95 | -2.21 | -2.35 |
| Normalized Basic EPS | -1.00 | -1.14 | -1.15 | -1.32 | -1.40 |
| EPS Diluted | -1.65 | -1.91 | -1.95 | -2.21 | -2.35 |
| Normalized Diluted EPS | -1.00 | -1.14 | -1.15 | -1.32 | -1.40 |
| Average Basic Shares Outstanding | 219.48M | 198.84M | 178.27M | 168.51M | 167.90M |
| Average Diluted Shares Outstanding | 219.48M | 198.84M | 178.27M | 168.51M | 167.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
